Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 39M | 33M | 32M | 22M | 25M |
| Gross Profit | 29M | 24M | -3M | -3M | 17M |
| Operating Income | 3M | -11M | -14M | -16M | -5M |
| EBITDA | 2M | -29M | -4M | -13M | -13M |
| Net Income | 94K | -41M | -6M | -12M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.37
+0.00% today
1Y Change
+15.41%
Window
Jun 27, 2025 → Jun 18, 2026
Coverage: 251 bars · Jun 27, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Medical Developments International Limited (MDDVF) is a Healthcare stock with a market cap of $50.00M and listed on OTC. The stock last traded around $0.37 and up 15.4% across the available one-year price window (Jun 27, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +17.8%, EPS growth of +100.2%, a dividend yield of 0.0%. What stands out right now is revenue +17.8%, EPS +100.2%, free cash flow +96.5% with operating margin 0.8% and ROIC 0.6%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines MDDVF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
MDDVF is 6.03 pts behind over the shared 1Y window.
MDDVF had 3.89 pts shallower max drawdown than SPY.
MDDVF beat SPY in 1 of 2 calendar years shown and trailed in 1.
MDDVF
+15.41%
Normalized return
SPY
+21.44%
S&P 500
Excess Return
-6.03 pts
Relative to SPY
MDDVF Max Drawdown
-5.24%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for MDDVF and SPY.
| Year | MDDVF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +21.79% | +6.71% | +15.08 pts | MDDVF |
| 2025 | -5.24% | +11.73% | -16.97 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$25.3M
+15.2% YoY
FY Net Income
-$12.6M
-1.3% YoY
Free Cash Flow
-$15.4M
+3.6% YoY
Revenue Growth
+17.8%
EPS Growth
+100.2%
Gross Margin
52.7%
Net Margin
-1.1%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 39M | 33M | 32M | 22M | 25M |
| Gross Profit | 29M | 24M | -3M | -3M | 17M |
| Operating Income | 3M | -11M | -14M | -16M | -5M |
| EBITDA | 2M | -29M | -4M | -13M | -13M |
| Net Income | 94K | -41M | -6M | -12M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 10M | 25M | 20M | 36M |
| Total Assets | 66M | 59M | 109M | 101M | 100M |
| Total Liabilities | 11M | 13M | 28M | 44M | 32M |
| Shareholder Equity | 55M | 46M | 81M | 57M | 68M |
| Total Debt | 2M | 2M | 3M | 3M | 3M |
| Net Debt | -16M | -7M | -22M | -18M | -33M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+17.9% YoY
Capital Expenditures
7M
-25.8% YoY
Free Cash Flow
15M
+3.6% YoY
Key ratios
Gross Margin
52.7%
Operating Margin
0.8%
Net Margin
-1.1%
ROE
-0.8%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.